Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Ranbaxy Obtains Approval To Market Ran-Rosuvastatin In Canada - Quick Facts

Ranbaxy Pharmaceuticals Canada Inc. or RPCI, a wholly owned subsidiary of Ranbaxy Laboratories Limited, announced that RPCI has received approval from Health Canada to manufacture and market RAN-Rosuvastatin tablets to the Canadian healthcare system. Rosuvastatin is a HMG-COA Reductase Inhibitor (cholesterol-lowering medication). Brand sales of Crestorin Canada were $742.2 million.

"The finished dosage form was developed, and will be manufactured within RLL's Health Canada approved facilities located in India. We anticipate making Rosuvastatin tablets available to all classes of trade after April 2 when sufficient supplies are available to meet market demand," said Paul Drake, President and General Manager of RPCI.

Click here to receive FREE breaking news email alerts for RANBAXY LABS LTD and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
The European Central Bank announced Thursday the results of its first targeted longer term refinancing operation, or TLTRO, which is aimed to boost liquidity at Eurozone banks to help revive lending to small businesses and households. The central bank announced that 255 bidders were allotted EUR 82.60... The Swiss National Bank on Thursday reaffirmed its currency ceiling and interest rate unchanged, as expected by economists, and expressed willingness to do more to defend the franc. The central bank maintained the minimum exchange rate of CHF 1.20 per euro and left the target range for the three-month Libor unchanged at 0.0-0.25 percent. The South Korean government said Thursday it will increase the budget spending next year and run a wider fiscal deficit than expected to bolster economic growth that faces challenges from slow global recovery and weak domestic demand. Government spending will rise by 5.7 percent to KRW 376 trillion the next year, the finance ministry said in its budget proposals.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.